This supports the notion that this novel class of immunostimulatory siRNA can potentiate the RIG-I signaling pathway in cancer cells, intensifying apoptotic signals and immune responses within tumor cells and tissues, thereby eliciting a stronger anti-tumor impact. This evidence concerns the gene RIGI and neoplasm.